VCMCVC Market Cap
Menu

Amoun Pharmaceutical valuation, funding and investors

Amoun Pharmaceutical works in pharmaceutical product development, based in Cairo, Egypt. Founded in 1998, it has about 1,130 employees.

Pharmaceutical Products Growth Equity
VALUATION · TODAY
$4.26B −1% after Growth
Range $298M – $10.23B · Grade D
TODAY
+12 MO
$2.50B
$5.00B
$7.50B
$10.00B
$12.50B
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021
2023
2025
2027
Growth $740M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY1,127 employees
−0%6m growth
−1%1y growth
+2%2y growth
500
1,000
1,500
Data from Feb 2024
TODAY
Predicted in 1 yr $4.22B −1% vs today
Predicted next raise $814M if a round comes
Winding-down probability 4%
Last round
Growth · $740M · Mar 2021
Valuation at last round
$6.74B · implied
Headcount
1,127 · flat
Grade
D
Founded
1998
How VCMC values companies →

Amoun Pharmaceutical valuation today

VCMC values Amoun Pharmaceutical at $4.3B today, with a range of $298M to $10.2B and a grade of D. The valuation starts from its last funding round, a growth round in Mar 2021.

Valuation by date (347 rows)

Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.

Amoun Pharmaceutical: valuation by date, as the model would have shown it on each date
DateValuationRangePredicted in 1 yrPhaseHeadcountTrendGradeWinding-down probability
1 Jan 1998$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 1998$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 1998$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 1998$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 1998$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 1998$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 1998$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 1998$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 1998$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 1998$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 1998$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 1998$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 1999$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 1999$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 1999$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 1999$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 1999$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 1999$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 1999$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 1999$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 1999$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 1999$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 1999$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 1999$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 2000$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 2000$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 2000$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 2000$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 2000$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 2000$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 2000$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 2000$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 2000$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 2000$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 2000$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 2000$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 2001$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 2001$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 2001$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 2001$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 2001$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 2001$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 2001$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 2001$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 2001$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 2001$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 2001$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 2001$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 2002$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 2002$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 2002$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 2002$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 2002$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 2002$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 2002$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 2002$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 2002$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 2002$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 2002$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 2002$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 2003$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 2003$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 2003$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 2003$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 2003$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 2003$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 2003$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 2003$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 2003$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 2003$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 2003$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 2003$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 2004$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 2004$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 2004$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 2004$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 2004$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 2004$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 2004$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 2004$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 2004$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 2004$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 2004$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 2004$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 2005$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 2005$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 2005$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 2005$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 2005$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 2005$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 2005$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 2005$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 2005$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 2005$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 2005$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 2005$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 2006$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 2006$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 2006$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 2006$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 2006$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 2006$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 2006$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 2006$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 2006$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 2006$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 2006$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 2006$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 2007$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 2007$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 2007$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 2007$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 2007$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 2007$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 2007$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 2007$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 2007$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 2007$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 2007$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 2007$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 2008$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 2008$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 2008$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 2008$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 2008$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 2008$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 2008$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 2008$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 2008$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 2008$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 2008$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 2008$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 2009$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 2009$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 2009$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 2009$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 2009$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 2009$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 2009$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 2009$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 2009$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 2009$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 2009$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 2009$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 2010$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 2010$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 2010$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 2010$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 2010$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 2010$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 2010$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 2010$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Sep 2010$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Oct 2010$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Nov 2010$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Dec 2010$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jan 2011$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Feb 2011$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Mar 2011$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Apr 2011$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 May 2011$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jun 2011$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Jul 2011$2.41M$0.88M – $6.61M$2.41M (0%)before first round–unknownD0%
1 Aug 2011$2.41M$0.88M – $6.61M$2.42M (0%)before first round–unknownD0%
1 Sep 2011$2.41M$0.88M – $6.61M$2.42M (+1%)before first round–unknownD0%
1 Oct 2011$2.41M$0.88M – $6.61M$2.43M (+1%)before first round–unknownD0%
1 Nov 2011$2.41M$0.88M – $6.61M$2.44M (+2%)before first round–unknownD0%
1 Dec 2011$2.41M$0.88M – $6.61M$2.45M (+2%)before first round–unknownD0%
1 Jan 2012$2.41M$0.88M – $6.61M$2.46M (+2%)before first round–unknownD0%
1 Feb 2012$2.41M$0.88M – $6.61M$2.47M (+3%)before first round–unknownD0%
1 Mar 2012$2.41M$0.88M – $6.61M$2.48M (+3%)before first round–unknownD0%
1 Apr 2012$2.41M$0.88M – $6.61M$2.49M (+4%)before first round–unknownD0%
1 May 2012$2.41M$0.88M – $6.61M$2.50M (+4%)before first round–unknownD0%
1 Jun 2012$2.41M$0.88M – $6.61M$2.51M (+4%)before first round–unknownD0%
1 Jul 2012$2.41M$0.88M – $6.61M$2.52M (+5%)before first round–unknownD0%
1 Aug 2012$2.42M$0.88M – $6.64M$2.53M (+5%)before first round–unknownD0%
1 Sep 2012$2.43M$0.88M – $6.66M$2.54M (+5%)before first round–unknownD0%
1 Oct 2012$2.43M$0.89M – $6.69M$2.55M (+5%)before first round–unknownD0%
1 Nov 2012$2.44M$0.89M – $6.71M$2.56M (+5%)before first round–unknownD0%
1 Dec 2012$2.45M$0.89M – $6.74M$2.57M (+5%)before first round–unknownD0%
1 Jan 2013$2.46M$0.90M – $6.77M$2.58M (+5%)before first round–unknownD0%
1 Feb 2013$2.47M$0.90M – $6.79M$2.59M (+5%)before first round–unknownD0%
1 Mar 2013$2.48M$0.90M – $6.82M$2.60M (+5%)before first round–unknownD0%
1 Apr 2013$2.49M$0.91M – $6.84M$2.61M (+5%)before first round–unknownD0%
1 May 2013$2.50M$0.91M – $6.87M$2.62M (+5%)before first round–unknownD0%
1 Jun 2013$2.51M$0.91M – $6.90M$2.63M (+5%)before first round–unknownD0%
1 Jul 2013$2.52M$0.92M – $6.93M$2.64M (+5%)before first round–unknownD0%
1 Aug 2013$2.53M$0.92M – $6.95M$2.65M (+5%)before first round–unknownD0%
1 Sep 2013$2.54M$0.93M – $6.98M$2.66M (+5%)before first round–unknownD0%
1 Oct 2013$2.55M$0.93M – $7.01M$2.67M (+5%)before first round–unknownD0%
1 Nov 2013$2.56M$0.93M – $7.04M$2.68M (+5%)before first round–unknownD0%
1 Dec 2013$2.57M$0.94M – $7.06M$2.69M (+5%)before first round–unknownD0%
1 Jan 2014$2.58M$0.94M – $7.09M$2.71M (+5%)before first round–unknownD0%
1 Feb 2014$2.59M$0.94M – $7.12M$2.72M (+5%)before first round–unknownD0%
1 Mar 2014$2.60M$0.95M – $7.14M$2.73M (+5%)before first round–unknownD0%
1 Apr 2014$2.61M$0.95M – $7.17M$2.74M (+5%)before first round–unknownD0%
1 May 2014$2.62M$0.95M – $7.20M$2.75M (+5%)before first round–unknownD0%
1 Jun 2014$2.63M$0.96M – $7.23M$2.76M (+5%)before first round–unknownD0%
1 Jul 2014$2.64M$0.96M – $7.26M$2.77M (+5%)before first round–unknownD0%
1 Aug 2014$2.65M$0.97M – $7.29M$2.78M (+5%)before first round–unknownD0%
1 Sep 2014$2.66M$0.97M – $7.32M$2.79M (+5%)before first round–unknownD0%
1 Oct 2014$2.67M$0.97M – $7.34M$2.80M (+5%)before first round–unknownD0%
1 Nov 2014$2.68M$0.98M – $7.37M$2.81M (+5%)before first round–unknownD0%
1 Dec 2014$2.69M$0.98M – $7.40M$2.82M (+5%)before first round–unknownD0%
1 Jan 2015$2.71M$0.98M – $7.43M$2.83M (+5%)before first round–unknownD0%
1 Feb 2015$2.72M$0.99M – $7.46M$2.85M (+5%)before first round–unknownD0%
1 Mar 2015$2.73M$0.99M – $7.49M$2.86M (+5%)before first round–unknownD0%
1 Apr 2015$2.74M$1.00M – $7.52M$2.87M (+5%)before first round–unknownD0%
1 May 2015$2.75M$1.00M – $7.55M$2.88M (+5%)before first round–unknownD0%
1 Jun 2015$2.76M$1.00M – $7.58M$2.89M (+5%)before first round–unknownD0%
1 Jul 2015$2.77M$1.01M – $7.61M$2.90M (+5%)before first round–unknownD0%
1 Aug 2015$2.78M$1.01M – $7.64M$2.98M (+7%)before first round–unknownD0%
1 Sep 2015$2.79M$1.02M – $7.67M$3.06M (+10%)before first round–unknownD0%
1 Oct 2015$2.80M$1.02M – $7.70M$3.14M (+12%)before first round–unknownD0%
1 Nov 2015$2.81M$1.02M – $7.73M$3.22M (+15%)before first round–unknownD0%
1 Dec 2015$2.82M$1.03M – $7.76M$3.31M (+17%)before first round–unknownD0%
1 Jan 2016$2.83M$1.03M – $7.79M$3.40M (+20%)before first round–unknownD0%
1 Feb 2016$2.85M$1.04M – $7.82M$3.49M (+23%)before first round–unknownD0%
1 Mar 2016$2.86M$1.04M – $7.85M$3.58M (+25%)before first round–unknownD0%
1 Apr 2016$2.87M$1.04M – $7.88M$3.68M (+28%)before first round–unknownD0%
1 May 2016$2.88M$1.05M – $7.91M$3.77M (+31%)before first round–unknownD0%
1 Jun 2016$2.89M$1.05M – $7.94M$3.87M (+34%)before first round–unknownD0%
1 Jul 2016$2.90M$1.06M – $7.97M$3.98M (+37%)before first round–unknownD0%
1 Aug 2016$2.98M$1.08M – $8.18M$4.08M (+37%)before first round–unknownD0%
1 Sep 2016$3.06M$1.11M – $8.41M$4.20M (+37%)before first round–unknownD0%
1 Oct 2016$3.14M$1.14M – $8.63M$4.31M (+37%)before first round–unknownD0%
1 Nov 2016$3.23M$1.17M – $8.86M$4.42M (+37%)before first round–unknownD0%
1 Dec 2016$3.31M$1.21M – $9.09M$4.54M (+37%)before first round–unknownD0%
1 Jan 2017$3.40M$1.24M – $9.33M$4.66M (+37%)before first round–unknownD0%
1 Feb 2017$3.49M$1.27M – $9.59M$4.79M (+37%)before first round–unknownD0%
1 Mar 2017$3.58M$1.30M – $9.82M$4.90M (+37%)before first round–unknownD0%
1 Apr 2017$3.67M$1.34M – $10.1M$5.04M (+37%)before first round–unknownD0%
1 May 2017$3.77M$1.37M – $10.4M$5.17M (+37%)before first round–unknownD0%
1 Jun 2017$3.87M$1.41M – $10.6M$5.31M (+37%)before first round–unknownD0%
1 Jul 2017$3.97M$1.45M – $10.9M$5.45M (+37%)before first round–unknownD0%
1 Aug 2017$4.08M$1.49M – $11.2M$5.60M (+37%)before first round–unknownD0%
1 Sep 2017$4.19M$1.53M – $11.5M$5.75M (+37%)before first round–unknownD0%
1 Oct 2017$4.30M$1.57M – $11.8M$5.90M (+37%)before first round–unknownD0%
1 Nov 2017$4.42M$1.61M – $12.1M$6.06M (+37%)before first round–unknownD0%
1 Dec 2017$4.53M$1.65M – $12.5M$6.22M (+37%)before first round–unknownD0%
1 Jan 2018$4.66M$1.70M – $12.8M$6.39M (+37%)before first round–unknownD0%
1 Feb 2018$4.79M$1.74M – $13.1M$6.56M (+37%)before first round–unknownD0%
1 Mar 2018$4.90M$1.78M – $13.5M$6.72M (+37%)before first round–unknownD0%
1 Apr 2018$5.04M$1.83M – $13.8M$6.90M (+37%)before first round–unknownD0%
1 May 2018$5.17M$1.88M – $14.2M$7.08M (+37%)before first round–unknownD0%
1 Jun 2018$5.31M$1.93M – $14.6M$7.28M (+37%)before first round–unknownD0%
1 Jul 2018$5.45M$1.98M – $15.0M$7.47M (+37%)before first round–unknownD0%
1 Aug 2018$5.60M$2.04M – $15.4M$7.54M (+35%)before first round–unknownD0%
1 Sep 2018$5.75M$2.09M – $15.8M$7.61M (+32%)before first round–unknownD0%
1 Oct 2018$5.90M$2.15M – $16.2M$7.68M (+30%)before first round–unknownD0%
1 Nov 2018$6.06M$2.21M – $16.6M$7.75M (+28%)before first round–unknownD0%
1 Dec 2018$6.22M$2.26M – $17.1M$7.82M (+26%)before first round–unknownD0%
1 Jan 2019$6.39M$2.33M – $17.5M$7.89M (+24%)before first round–unknownD0%
1 Feb 2019$6.56M$2.39M – $18.0M$7.96M (+21%)before first round–unknownD0%
1 Mar 2019$6.72M$2.45M – $18.5M$8.03M (+19%)before first round–unknownD0%
1 Apr 2019$6.90M$2.51M – $19.0M$8.10M (+17%)before first round–unknownD0%
1 May 2019$7.08M$2.58M – $19.5M$8.18M (+15%)before first round–unknownD0%
1 Jun 2019$7.28M$2.65M – $20.0M$8.25M (+13%)before first round–unknownD0%
1 Jul 2019$7.47M$2.72M – $20.5M$8.32M (+11%)before first round–unknownD0%
1 Aug 2019$7.54M$2.75M – $20.7M$8.40M (+11%)before first round–unknownD0%
1 Sep 2019$7.61M$2.77M – $20.9M$8.48M (+11%)before first round–unknownD0%
1 Oct 2019$7.68M$2.80M – $21.1M$8.55M (+11%)before first round–unknownD0%
1 Nov 2019$7.75M$2.82M – $21.3M$8.63M (+11%)before first round–unknownD0%
1 Dec 2019$7.82M$2.85M – $21.5M$8.71M (+11%)before first round–unknownD0%
1 Jan 2020$7.89M$2.87M – $21.7M$8.79M (+11%)before first round–unknownD0%
1 Feb 2020$7.96M$2.90M – $21.9M$8.87M (+11%)before first round–unknownD0%
1 Mar 2020$8.03M$2.92M – $22.1M$8.95M (+11%)before first round–unknownD0%
1 Apr 2020$8.11M$2.95M – $22.3M$9.03M (+11%)before first round–unknownD0%
1 May 2020$8.18M$2.98M – $22.5M$9.11M (+11%)before first round–unknownD0%
1 Jun 2020$8.25M$3.00M – $22.7M$9.19M (+11%)before first round–unknownD0%
1 Jul 2020$8.33M$3.03M – $22.9M$9.27M (+11%)before first round–unknownD0%
1 Aug 2020$8.40M$3.06M – $23.1M$9.36M (+11%)before first round–unknownD0%
1 Sep 2020$8.48M$3.09M – $23.3M$9.45M (+11%)before first round–unknownD0%
1 Oct 2020$8.56M$3.11M – $23.5M$9.53M (+11%)before first round–unknownD0%
1 Nov 2020$8.63M$3.14M – $23.7M$9.62M (+11%)before first round–unknownD0%
1 Dec 2020$8.71M$3.17M – $23.9M$9.70M (+11%)before first round–unknownD0%
1 Jan 2021$8.79M$3.20M – $24.1M$9.79M (+11%)before first round–unknownD0%
1 Feb 2021$8.87M$3.23M – $24.4M$9.86M (+11%)before first round–unknownD0%
1 Mar 2021$8.94M$3.26M – $24.6M$9.93M (+11%)before first round–unknownD0%
1 Apr 2021$6.7B$4.4B – $11.3B$7.4B (+10%)after a round–unknownB0%
1 May 2021$6.8B$4.4B – $11.3B$7.4B (+9%)after a round–unknownB0%
1 Jun 2021$6.8B$4.4B – $11.3B$7.4B (+8%)after a round–unknownB0%
1 Jul 2021$6.9B$4.4B – $11.3B$7.4B (+7%)after a round–unknownB0%
1 Aug 2021$7.0B$4.4B – $11.3B$7.4B (+7%)after a round–unknownB0%
1 Sep 2021$7.0B$4.4B – $11.3B$7.4B (+6%)after a round–unknownB0%
1 Oct 2021$7.1B$4.4B – $11.3B$7.4B (+5%)after a round–unknownB0%
1 Nov 2021$7.1B$4.4B – $11.3B$7.4B (+4%)after a round–unknownB0%
1 Dec 2021$7.2B$4.4B – $11.3B$7.4B (+3%)after a round–unknownB0%
1 Jan 2022$7.2B$4.4B – $11.3B$7.4B (+2%)after a round–unknownB0%
1 Feb 2022$7.3B$4.4B – $11.3B$7.4B (+2%)after a round–unknownB0%
1 Mar 2022$7.4B$4.4B – $11.3B$7.4B (+1%)after a round–unknownB0%
1 Apr 2022$7.4B$4.4B – $11.3B$7.4B (0%)after a round–unknownB0%
1 May 2022$7.4B$4.2B – $11.3B$7.4B (0%)after a round–unknownB0%
1 Jun 2022$7.4B$4.0B – $11.3B$7.4B (0%)after a round–unknownB0%
1 Jul 2022$7.4B$3.8B – $11.3B$7.4B (0%)after a round–unknownB0%
1 Aug 2022$7.4B$3.6B – $11.3B$7.4B (0%)after a round–unknownB0%
1 Sep 2022$7.4B$3.4B – $11.3B$7.4B (0%)after a round–unknownB0%
1 Oct 2022$7.4B$3.3B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Nov 2022$7.4B$3.1B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Dec 2022$7.4B$3.0B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Jan 2023$7.4B$2.8B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Feb 2023$7.4B$2.7B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Mar 2023$7.4B$2.6B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Apr 2023$7.4B$2.4B – $11.3B$7.4B (0%)after a round–unknownC0%
1 May 2023$7.4B$2.3B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Jun 2023$7.4B$2.2B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Jul 2023$7.4B$2.1B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Aug 2023$7.4B$2.0B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Sep 2023$7.4B$1.9B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Oct 2023$7.4B$1.8B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Nov 2023$7.4B$1.7B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Dec 2023$7.4B$1.6B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Jan 2024$7.4B$1.5B – $11.3B$7.4B (0%)after a round–unknownC0%
1 Feb 2024$7.4B$1.5B – $11.3B$7.4B (0%)after a round980unknownD0%
1 Mar 2024$7.4B$1.4B – $11.3B$6.8B (-9%)after a round980flatD0%
1 Apr 2024$7.4B$1.3B – $11.3B$6.7B (-9%)after a round980flatD0%
1 May 2024$7.4B$1.3B – $11.2B$6.7B (-8%)after a round980flatD0%
1 Jun 2024$7.3B$1.2B – $11.1B$6.7B (-8%)after a round980flatD0%
1 Jul 2024$7.2B$1.1B – $11.0B$6.7B (-7%)after a round980flatD0%
1 Aug 2024$7.3B$1.4B – $11.1B$6.9B (-6%)after a round1,100upD0%
1 Sep 2024$7.2B$1.3B – $11.0B$6.8B (-6%)after a round1,100upD0%
1 Oct 2024$7.2B$1.3B – $11.0B$6.8B (-6%)after a round1,100upD0%
1 Nov 2024$7.2B$1.2B – $10.9B$6.8B (-5%)after a round1,100upD0%
1 Dec 2024$7.1B$1.2B – $10.9B$6.8B (-5%)after a round1,100upD0%
1 Jan 2025$7.1B$1.1B – $10.8B$6.7B (-5%)after a round1,100upD0%
1 Feb 2025$7.1B$1.1B – $10.8B$6.7B (-5%)after a round1,100upD0%
1 Mar 2025$7.0B$1.0B – $10.7B$6.7B (-4%)after a round1,100upD0%
1 Apr 2025$7.0B$1.1B – $10.7B$6.7B (-4%)after a round1,100upD0%
1 May 2025$7.0B$1.1B – $10.6B$6.7B (-3%)after a round1,100upD0%
1 Jun 2025$7.0B$1.0B – $10.6B$6.7B (-3%)after a round1,100upD0%
1 Jul 2025$7.0B$989M – $10.6B$6.7B (-4%)after a round1,137upD0%
1 Aug 2025$6.9B$951M – $10.5B$6.7B (-3%)after a round1,133upD0%
1 Sep 2025$6.8B$914M – $10.4B$6.7B (-1%)after a round1,135upD0%
1 Oct 2025$6.7B$541M – $10.3B$6.7B (0%)after a round1,135flatD0%
1 Nov 2025$6.7B$514M – $10.3B$6.7B (0%)after a round1,135flatD0%
1 Dec 2025$6.7B$489M – $10.3B$6.7B (0%)after a round1,135flatD0%
1 Jan 2026$6.7B$465M – $10.3B$6.7B (0%)after a round1,135flatD0%
1 Feb 2026$6.7B$443M – $10.3B$6.7B (0%)after a round1,131flatD0%
1 Mar 2026$6.7B$443M – $10.3B$6.7B (0%)after a round1,131flatD0%
1 Apr 2026$6.7B$443M – $10.3B$6.7B (0%)after a round1,131flatD0%
1 May 2026$6.7B$443M – $10.3B$6.7B (0%)after a round1,131flatD0%
1 Jun 2026$6.3B$443M – $10.2B$6.3B (-1%)after a round1,127flatD4%
1 Jul 2026$6.3B$443M – $10.2B$6.3B (-1%)after a round1,127flatD4%
1 Aug 2026$6.3B$443M – $10.2B$6.3B (-1%)after a round1,127flatD4%
1 Sep 2026$6.3B$443M – $10.2B$6.3B (-1%)after a round1,127flatD4%
1 Oct 2026$6.3B$443M – $10.2B$6.3B (-1%)after a round1,127flatD4%
24 Oct 2026$4.3B$298M – $10.2B$4.2B (-1%)after a round1,127flatD4%

Key facts about Amoun Pharmaceutical

Founded
1998
Headquarters
Cairo, Egypt
Employees
about 1,130 +3% in a year
Total raised
$740M
Funding rounds
1
Last round
Growth Equity Mar 2021

Amoun Pharmaceutical was founded in 1998 by Tharwat Bassily.

Amoun Pharmaceutical funding history

Amoun Pharmaceutical has 1 funding round on record, from Mar 2021 to Mar 2021, $740M in total. None disclosed a valuation.

  1. Growth Equity 31 Mar 2021

    With ADQ.

    Sources: prnewswire.com, thestar.com

    $740M

Amoun Pharmaceutical investors

1 investor has backed Amoun Pharmaceutical.

  • ADQ

What Amoun Pharmaceutical does

Amoun Pharmaceutical works in pharmaceutical products, with 14 recorded offerings and customers in healthcare.

Amoun Pharmaceutical Company S.A.E. is an Egyptian joint-stock company engaged in the development, manufacturing, marketing, distribution, and export of human pharmaceutical products. The company operates a large-scale pharmaceutical manufacturing facility and maintains a commercial office network across Egypt and the UAE. Amoun Pharmaceutical serves both domestic and international markets, supplying medications and therapies to healthcare providers and patients in over 29 countries. The company also manages pharmacovigilance activities to ensure product safety and efficacy.

Description from Veridion's company data.

Products and services

  • Pharmaceutical Product Development
  • Pharmaceutical Product Manufacturing
  • Pharmaceutical Product Marketing
  • Pharmaceutical Product Distribution
  • Pharmaceutical Product Export
  • Life-Saving Medication Manufacturing
  • Advanced Therapy Development
  • Pharmaceutical Product Exporting
  • Pharmacovigilance Services
  • Product Pipeline Management
  • Healthcare Solutions Development
  • International Pharmaceutical Collaboration
  • Regulatory Compliance Consulting
  • Patient Quality of Life Improvement Services

Markets

  • Healthcare

Business model

  • Business-to-Business
  • Manufacturing
  • Wholesale

Industry codes (NAICS)

  • 325412 Pharmaceutical Preparation Manufacturing 70% match
  • 424210 Drugs and Druggists' Sundries Merchant Wholesalers 30% match

Questions about Amoun Pharmaceutical

What is Amoun Pharmaceutical worth?

Valuation $4.3B (range $298M to $10.2B), as of 24 Oct 2026.

Has Amoun Pharmaceutical raised money?

Amoun Pharmaceutical has 1 funding round on record, from Mar 2021 to Mar 2021, $740M in total. None disclosed a valuation.

Who has invested in Amoun Pharmaceutical?

ADQ.

How many people work at Amoun Pharmaceutical?

About 1,130, up 3% over the last year. Headcount grew from 980 in Feb 2024 to 1,127 in Jun 2026.

What does Amoun Pharmaceutical do?

Amoun Pharmaceutical works in pharmaceutical products, with 14 recorded offerings and customers in healthcare. Its main offerings are pharmaceutical product development, pharmaceutical product manufacturing and pharmaceutical product marketing.

When was Amoun Pharmaceutical founded, and where is it based?

Amoun Pharmaceutical was founded in 1998 and is based in Cairo, Egypt. It has about 1,130 employees, up 3% over the last year.